-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $64

Benzinga·12/17/2025 15:11:22
Listen to the news
Citigroup analyst Samantha Semenkow initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $64.